Alvotech SDB

ALVO-SDB · Nasdaq Stockholm · Healthcare

55.20SEK −0.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: −28.3%

Performance

1 month

+11.3%

1 year

−28.3%

3 years, per year

–

5 years, per year

–

Largest fall, 3 years

−75.4%

Below the peak now

−51.2%

Volatility, 1 year

77.4%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

−7.0

Dividend yield

0.0%

Return on equity

−93.8%

Net margin

−36.5%

Market value

2.0 bn USD

Quality, value and trend

Where Alvotech SDB stands against every Nordic stock today. 100 is best.

Quality0

Profitability and a sound balance sheet over time. Better than 0% of Nordic stocks.

Value6

The price measured against earnings, assets and cash flow. Better than 6% of Nordic stocks.

Trend75

The price development over the past year. Better than 75% of Nordic stocks.

Combined11

Quality, value and trend together. Better than 11% of Nordic stocks.

About Alvotech SDB

Alvotech SDB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1,300 employees.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosi…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis